Washington court: Health plan obesity drug exclusions may violate anti-discrimination law

A Washington state appellate court ruled that a health plan's blanket exclusion of coverage for obesity drugs may violate state anti-discrimination laws. The decision challenges a common cost-containment strategy used by commercial payers and self-insured employer plans. This legal precedent could force insurers in Washington to re-evaluate and potentially revise pharmacy benefit exclusions for GLP-1 agonists and other anti-obesity medications. Billing and prior authorization teams should prepare for potential shifts in coverage policies from payers operating in Washington, which may ripple to other states. Review current denial patterns for drugs like semaglutide and tirzepatide; if you have Washington-based patients facing denials, this ruling provides a new basis for appeals. Monitor payer communications for any immediate policy updates.